Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07830199
PHASE1

A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

View on ClinicalTrials.gov

Summary

The study is being conducted to evaluate the safety and tolerability of SHR-4595 for injection in participants with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended dose for Phase II clinical studies (RP2D) of SHR-4595.

Official title: An Open-label, Multicenter Phase I Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

208

Start Date

2026-09

Completion Date

2030-12

Last Updated

2026-09-21

Healthy Volunteers

No

Conditions

Interventions

DRUG

SHR-4595 for Injection

SHR-4595 for injection, in different doses.

Locations (2)

Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute)

Shenyang, Liaoning, China

Tianjin Cancer Hospital

Tianjin, Tianjin Municipality, China